XML 25 R37.htm IDEA: XBRL DOCUMENT v3.2.0.727
Summary of Significant Accounting Policies (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
May. 19, 2014
USD ($)
Sep. 30, 2014
USD ($)
May. 31, 2014
USD ($)
Dec. 31, 2014
USD ($)
Sep. 30, 2014
USD ($)
Dec. 31, 2014
USD ($)
item
Components of collaboration revenue            
Total collaboration revenue       $ 1,684 $ 39,575 $ 41,259
Number of categories for milestones | item           3
License revenue            
Components of collaboration revenue            
Total collaboration revenue           $ 38,372
Research and development activity revenue            
Components of collaboration revenue            
Total collaboration revenue           2,004
API transfer revenue            
Components of collaboration revenue            
Total collaboration revenue           883
Novartis Pharma AG            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Upfront fees received     $ 200,000     200,000
Patient enrollment-based milestone revenue achieved   $ 50,000        
Novartis Pharma AG | Licensing and Commercialization Agreement            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Upfront fees received $ 200,000          
Novartis Pharma AG | Licensing and Commercialization Agreement | API transfer revenue            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Recognized revenues           900
Novartis Pharma AG | Licensing and Commercialization Agreement | Achievement of specified patient enrollment milestones            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Patient enrollment-based milestone revenue achieved   $ 50,000        
Recognized revenues           41,300
Novartis Pharma AG | Licensing and Commercialization Agreement | Achievement of specified patient enrollment milestones | License revenue            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Recognized revenues           38,400
Novartis Pharma AG | Licensing and Commercialization Agreement | Achievement of specified patient enrollment milestones | Research and development activity revenue            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Recognized revenues           $ 2,000